Identification of prostate cancer potential therapeutic targets and virtual drug screening through combined Mendelian randomization study, Bayesian colocalization and molecular docking
Our study identified several protein biomarkers associated with PCa risk and screened potential compounds using molecular docking. These findings provide new insights and promising targets for PCa drug development, with beta-Amyrone showing strong potential as a dual-target inhibitor against both C5 and SCP2.
Authors
- Conglei Hu (ORCID: https://orcid.org/0009-0005-4902-1202)
- Z. Hugh Fan (ORCID: https://orcid.org/0000-0002-1812-8016)
- Lingchen Kong
- Fei Liu (ORCID: https://orcid.org/0000-0002-7398-2274)
- Yongxiang Shao
- Meng Cheng
- Haiyang Du (ORCID: https://orcid.org/0000-0001-7813-8585)
- Zhou Liang (ORCID: https://orcid.org/0000-0001-7369-366X)
- Liping Yao (ORCID: https://orcid.org/0009-0006-4146-5164)
- Haofeng Pang
- Tianxi Feng
Institutions
- Air Force General Hospital PLA (CN)
- Xijing Hospital (CN)
- Air Force Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1007/s12672-025-02968-4
- Primary Topic
- Genetic Associations and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China